The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis.

Discontinuation was driven by experience of side effects. Patients currently taking dimethyl fumarate were more likely to experience a side effect versus patients currently taking fingolimod. Examination of the relationship between tolerability and adherence/persistence is needed.